The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 67,858 | 3,080,237 | SH | SOLE | 3,080,237 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM | 56854Q101 | 17,459 | 1,431,058 | SH | SOLE | 1,431,058 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 53,517 | 7,060,353 | SH | SOLE | 7,060,353 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 30,765 | 8,891,758 | SH | SOLE | 8,891,758 | 0 | 0 | ||
| SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 528,040 | 7,281,307 | SH | SOLE | 7,281,307 | 0 | 0 | ||
| DYNAVAX TECHNOLOGIES CORP | COM | 268158901 | 48,486 | 10,895,773 | SH | SOLE | 10,895,773 | 0 | 0 | ||
| CONSTELLATION PHARMACEUTICALS, INC. | COM | 210373106 | 40,320 | 1,400,000 | SH | SOLE | 1,400,000 | 0 | 0 | ||
| X4 PHARMACEUTICALS INC | COM | 98420X103 | 10,600 | 1,648,485 | SH | SOLE | 1,648,485 | 0 | 0 | ||
| SAVARA INC | COM | 805111101 | 5,898 | 5,128,593 | SH | SOLE | 5,128,593 | 0 | 0 | ||
| ARCUTIS BIOTHERAPEUTICS, INC. | COM | 03969K108 | 111,937 | 3,979,292 | SH | SOLE | 3,979,292 | 0 | 0 | ||
| MERSANA THERAPEUTICS | COM | 59045L106 | 91,689 | 3,445,667 | SH | SOLE | 3,445,667 | 0 | 0 | ||
| CRINETICS PHAMACEUTICALS | COM | 22663K107 | 15,118 | 1,071,428 | SH | SOLE | 1,071,428 | 0 | 0 | ||
| AEGLEA BIO THERAPEUTICS | COM | 00773J103 | 21,249 | 2,700,000 | SH | SOLE | 2,700,000 | 0 | 0 | ||
| ANNEXON INC | COM | 03589W102 | 81,138 | 3,241,628 | SH | SOLE | 3,241,628 | 0 | 0 | ||
| NURIX THERAPEUTICS, INC. | COM | 67080M103 | 42,228 | 1,284,314 | SH | SOLE | 1,284,314 | 0 | 0 | ||
| KYMERA THERAPEUTICS INC. | COM | 501575104 | 29,735 | 479,605 | SH | SOLE | 479,605 | 0 | 0 | ||
| THERAPEUTICS ACQUISITION COR | COM CL A | 88339T103 | 13,920 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| ARYA SCIENCES ACQUISITION CORP III | COM CL A | G3166W106 | 10,850 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| BCTG ACQUISITION CORP | COM | 05492W103 | 5,720 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| SYROS PHARMACEUTICALS, INC. | COM | 87184Q107 | 62,768 | 5,785,036 | SH | SOLE | 5,785,036 | 0 | 0 | ||
| ATEA PHARMACEUTICALS, INC. | COM | 04683R106 | 234,622 | 5,615,659 | SH | SOLE | 5,615,659 | 0 | 0 | ||
| C4 THERAPEUTICS, INC. | COM STK | 12529R107 | 54,406 | 1,642,209 | SH | SOLE | 1,642,209 | 0 | 0 | ||
| BCLS ACQUISITION CORP | COM CL A | G0904B105 | 5,431 | 487,500 | SH | SOLE | 487,500 | 0 | 0 | ||
| JIYA ACQUISITION CORP | COM CL A | 47760M102 | 3,090 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| HELIX ACQUISITION CORP | COM CL A | G4444C102 | 2,843 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| FRAZIER LIFESCIENCES ACQUISITION CORP | UNIT 12/09/2025 | G3710A121 | 3,114 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||